Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Summary

This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative treatment option for HCC, however, up to 20% of patients develop recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Systemic treatments for HCC have not been studied in patients with recurrent HCC after liver transplantation, so there is no established therapy for these patients. This phase II trial evaluates lenvatinib for this purpose.

Timeline

Start

2022-04-19

Primary completion

2025-05-09

Completion

2025-05-09

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Accrual”

Drugs

Indications